Regional cerebral blood flow (CBF) was examined in 27 patients with Parkinson's disease using single-photon emission computed tomography and N-isopropyl-p-[123I]iodoamphetamine as a tracer. Their CBF pattern was compared with that of seven patients with Alzheimer's disease and nine age-matched neurologically normal controls. Tracer activity was determined in seven bilateral cerebellar, cortical, and subcortical regions and was expressed as the ratio of activity in each region to the mean tracer activity in the cerebellar region.
Nineteen patients with nondemented Parkinson's disease showed significantly decreased tracer activity ratio in the frontal and temporal cortices, basal ganglia, and thalamus compared with that in controls. The eight demented Parkinson's disease patients showed significantly decreased tracer activity ratio in the temporal and parietal cortices compared with the patients without dementia, and demonstrated CBF pattern similar to that of patients with Alzheimer's disease. These findings suggest that in patients with Parkinson's disease, the mechanism of CBF reduction of the frontal cortical region differs from that in the temporoparietal cortical region and support the concept that Parkinson's disease and Alzheimer's disease may overlap in some patients. (J Geriatr Psychiatry Neurol 1991;4:194-203).
Get full access to this article
View all access options for this article.
References
1.
Bès A., Güell A., Fabre N., et al: Cerebral blood flow studied by xenon-133 inhalation technique in parkinsonism: Loss of hyperfrontal pattern. J Cereb Blood Flow Metab1983;3:33-37.
2.
Wolfson LI, Leenders KL, Brown LL, Jones T.Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology1985;35:1399-1405.
3.
Globus M., Mildworf B., Melamed E.: Cerebral blood flow and cognitive impairment in Parkinson's disease . Neurology1985;35:1135-1139.
4.
Tachibana H. , Meyer JS, Kitagawa Y., et al: Xenon contrast CT-CBF measurements in parkinsonism and normal aging. J Am Geriatr Soc1985;33:413-421.
5.
Pizzolato G. , Dam M., Borsato N., et al: [99mTc]-HM-PAO SPECT in Parkinson's disease. J Cereb Blood Flow Metab1988;8:S101-S108.
6.
Calne DB: Is "Parkinson's disease" one disease? J Neurol Neurosurg Psychiatry1989;(Special Suppl):18-21.
7.
Gibb Wrg: Dementia and Parkinson's disease. Br J Psychiatry1989;154:596-614.
8.
Mayeux R., Stern Y., Rosen J., Benson F.: Is "subcortical dementia" a recognizable clinical entity?Ann Neurol1983 ;14:278-283.
9.
Cummings JL, Benson DF: Subcortical dementia. Review of an emerging concept. Arch Neurol1984;41:874-879.
10.
Hakim AM, Mathieson G.: Dementia in Parkinson disease: A neuropathologic study. Neurology1979;29:1209-1214.
11.
Candy JM, Perry RH, Perry EK, et al: Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's disease. J Neurol Sci1983 ;54:59:277-289.
12.
Whitehouse PJ , Hedreen JC, White CL III, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol1983;13:243-248.
13.
Winchell HS, Horst WD, Braun L., et al: N-Isopropyl [123I]p-iodoamphetamine: Single-pass brain uptake and washout; binding to brain synaptosomes; and localization in dog and monkey brain. J Nucl Med1980;21:947-952.
14.
Kuhl DE, Barrio JR, Huang SC, et al: Quantifying local cerebral blood flow by N-isopropyl-p[123I]iodoamphetamine (IMP) tomography. J Nucl Med1982;23:196-203.
15.
Hachinski VC , Iliff LD, Zilhka E., et al: Cerebral blood flow in dementia. Arch Neurol1975;32:632-637.
16.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, revised. American Psychiatric Press1987, pp103-107.
17.
Folstein MF , Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinicians . J Psychiatr Res1975;12:189-198.
18.
Hoehn MM, Yahr MD: Parkinsonism: Onset, progression, and mortality. Neurology1967;17:427-442.
19.
McKhann G., Drachman D., Folstein M., et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology1984 ;34:939-944.
20.
Morris JC, McKeel DW Jr, Fulling K., et al: Validation of clinical diagnostic criteria for Alzheimer's disease . Ann Neurol1988;24:17-22.
Wallenstein S., Zucker CZ, Fleiss JL: Some statistical methods useful in circulation research. Circ Res1980 ;47:1-9.
23.
Sorenson JA: Qualitative measurement of radioactivity in vivo by whole body counting , in Hine GJ, Sorenson JA (eds): Instrumentation in Nuclear Medicine, vol 2. New York, Academic Press, 1974, pp 311-324.
24.
Matsui T., Hirano A.: An atlas of the human brain for computerized tomography. New York, Igaku-Shoin, 1978.
25.
Akiyama H., Harrop R., McGeer PL, et al: Crossed cerebellar and uncrossed basal ganglia and thalamic diaschisis in Alzheimer's disease. Neurology1989;39:541--548.
26.
Tomlinson BE , Corsellis Jan: Aging and the dementias, in Adams JH, Corsellis JAN, Duchen LW (eds): Greenfield's Neuropathology , 4th ed. New York, John Wiley, 1984, pp 951-1025.
27.
Johnson KA, Mueller ST, Walshe TM, et al: Cerebral perfusion imaging in Alzheimer's disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol1987;44:165-168.
28.
Hellman RS, Tikofsky RS, Collier BD, et al: Alzheimer disease: Quantitative analysis of I-123-iodoamphetamine SPECT brain imaging. Radiology1989;172:183-188.
29.
Klinger A., de Leon MJ, Gerore AE, et al: Elevated cerebellar glucose metabolism in microvascular white matter disease: Normal aging and Alzheimer's disease. J Cereb Blood Flow Metab1988;8:433-435.
30.
McGeer PL, Kamo H., Harrop R., et al: Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. Can Med Assoc J1986;134:597-607.
31.
Moore RY, Bloom FE: Central catecholamine neuron systems: Anatomy and physiology of the dopamine systems. Ann Rev Neurosci1978;1:129-169.
Rougement D. , Baron JC, Collard P., et al: Local cerebral metabolic rate of glucose (ICMRglc) in treated and untreated patients with Parkinson's disease. J Cereb Blood Flow Metab1983;3(Suppl 1):S504-S505.
Henriksen L. , Boas J.Regional cerebral blood flow in hemiparkinsonian patients. Emission computerized tomography of inhaled 133xenon before and after levodopa. Acta Neurol Scand1985;71:257-266.
36.
Martin WR, Beckman JH, Calne DB, et al: Cerebral glucose metabolism in Parkinson's disease. Can J Neurol Sci1984;11 (Suppl 1):169-173.
37.
Guttman M., Seeman P.: Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy. Adv Neurol1987;45:51-57.
38.
Rinne UK, Sonninen V.: Brain catecholamines and their metabolites in parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. Arch Neurol1973;28:107-110.
39.
Ruberg M., Ploska A., Javoy-Agid F., Agid Y.: Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res1982;232:129-139.
40.
Lloyd KG, Shemen L., Hornykiewicz O.Distribution of high affinity sodium-independent [3H]gamma-aminobutyric acid ([3H]GABA) binding in the human brain: Alteration in Parkinson's disease . Brain Res1977;127:269-278.
41.
Studler JM, Javoy-Agid F., Cesselin F., et al: CCK-8-immunoreactivity distribution in human brain: Selective decrease in the substantia nigra from Parkinsonian patients. Brain Res1982;243:176-179.
42.
Frackowiak RS, Pozzilli C., Legg NJ, et al: Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain1981;104:753-778.
43.
Tachibana H. , Meyer JS, Kitagawa Y., et al: Effects of aging on cerebral blood flow in dementia. J Am Geriatr Soc1984;32:114-120.
44.
Huber SJ, Shuttleworth EC, Paulson GW, et al: Cortical vs subcortical dementia. Neuropsychological differences . Arch Neurol1986;43:392-394.
45.
Leiberman A. , Dziatolowski M., Kupersmith M., et al: Dementia in Parkinson's disease. Ann Neurol1979;6:355-359.
46.
Boller F., Mizutani T., Roessmann U., Gambetti P.: Parkinson disease, dementia, and Alzheimer disease: Clinicopathological correlations . Ann Neurol1980;7:329-335.
47.
Agid Y., Ruberg M., Dubois B., Javoy-Agid F.: Biochemical substrates of mental disturbances in Parkinson's disease , in Hessler RG, Christ JF (eds): Parkinson-Specific Motor and Mental Disorders . New York, Raven Press1984, pp 211-218.
48.
Stern MB, Gur RC, Saykin AJ, Hurtig HI: Dementia of Parkinson's disease and Alzheimer's disease. Is there a difference?J Am Geriatr Soc1986;34:475-478.
49.
Sharp P., Gemmell H., Cherryman G., et al: Application of iodine-123-labeled isopropylamphetamine imaging to the study of dementia. J Nucl Med1986;27:761-768.
50.
Cohen MB, Graham LS, Lake R., et al: Diagnosis of Alzheimer's disease and multiple infarct dementia by tomographic imaging of iodine-123 IMP. J Nucl Med1986;27:769-774.
51.
Gemmell HG, Sharp PF, Smith FW, et al: Cerebral blood flow measured by SPECT as a diagnostic tool in the study of dementia. Psychiatr Res1989;29:327-329.
52.
Miller BL, Mena I., Daly J., et al: Temporal-parietal hypoperfusion with single-photon emission computerized tomography in conditions other than Alzheimer's disease. Dementia1990;1:41-45.
53.
Boller F.: Mental status of patients with Parkinson's disease. J Clin Neuropsychol1980;2:157-172.
54.
Gaspar P., Gray F.: Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases. Acta Neuropathol1984;64:43-52.
